STOCK OPTION AGREEMENT (Director)Stock Option Agreement • January 30th, 2019 • AgeX Therapeutics, Inc. • Pharmaceutical preparations • Delaware
Contract Type FiledJanuary 30th, 2019 Company Industry JurisdictionTHIS AGREEMENT made and entered into as of ______, 20___, by and between AgeX Therapeutics, Inc., a Delaware corporation (the “Company”), and _________, a director (the “Optionee”) of the Company or of a subsidiary of the Company (hereinafter included within the term “Company”) within the meaning of Section 425(f) of the Internal Revenue Code of 1986, as amended (the “Code”),
STOCK OPTION AGREEMENT (Director)Stock Option Agreement • August 29th, 2018 • OncoCyte Corp • In vitro & in vivo diagnostic substances • California
Contract Type FiledAugust 29th, 2018 Company Industry JurisdictionTHIS AGREEMENT made and entered into as of ______, 20___, by and between OncoCyte Corporation, a California corporation (the “Company”), and _________, a director (the “Optionee”) of the Company or of a subsidiary of the Company (hereinafter included within the term “Company”) within the meaning of Section 425(f) of the Internal Revenue Code of 1986, as amended (the “Code”),
STOCK OPTION AGREEMENT (Director)Stock Option Agreement • November 12th, 2013 • Biotime Inc • Biological products, (no disgnostic substances) • California
Contract Type FiledNovember 12th, 2013 Company Industry JurisdictionTHIS AGREEMENT made and entered into as of ______, 20___, by and between BioTime, Inc., a California corporation (the "Company"), and _________, a director (the "Optionee") of the Company or of a subsidiary of the Company (hereinafter included within the term "Company") within the meaning of Section 425(f) of the Internal Revenue Code of 1986, as amended (the "Code"),
STOCK OPTION AGREEMENT (Director)Stock Option Agreement • August 13th, 2013 • Asterias Biotherapeutics, Inc. • Biological products, (no disgnostic substances) • Delaware
Contract Type FiledAugust 13th, 2013 Company Industry JurisdictionTHIS AGREEMENT made and entered into as of ______, 20___, by and between Asterias Biotherapeutics, Inc., a Delaware corporation (the “Company”), and _________, a director (the “Optionee”) of the Company.